Dr. Jozefien Roose

Active

Private limited companyfounded 2022active for 3 yearsSplithage 24, 8340 Damme, BelgiumKBO/BCE: BE 0795.265.881

From the official registers: KBO 3 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Dr. Jozefien Roose has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €238,459 and a net result of €129,520. Equity is growing by about 90% per year across the filed financial years. Its solvency ranks better than 79% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow Report Compare

Dr. Jozefien RooseActiveChecked score 98/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 22-12-2022 Normal situation
Legal form: Private limited company
Registered office: Splithage 24, 8340 Damme
Activity: Specialist medical practice NACE 86220
Establishment unit: 2.339.789.854 8340 Damme, since 22-12-2022
Financial year end: 31 December
Peppol: Reachable since 29-12-2025

Company details

Who decides

Board

ROOSE Jozefien Anne JohanDirector · since 21-12-2022

Holdings: Shares in 1 company Pediaters Brugge

Board & ownership

How it is doing

98 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: < 0.1%

Annual accounts 2025

Gross margin: €168,446; ▲ 95.1%
Turnover: ≈ €310,000; estimated
Profit: €129,520; ▲ 89.6%
Equity: €238,459; ▲ 119%
Total assets: €275,782; ▲ 114%

2025 accounts 25 days early

Filed on 06-07-2026at the National Bank

Financials

Why 98lowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 7.38, cash €257,950Equity €238,459 (86.5% of total assets)Size: total assets €275,782Show the evidence

Checked score

Score 2025

98 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 85% of its sector peers (NACE 86, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Strong

Solvency 100=

equity 86.5% of total assets

Liquidity 98+1

short-term debt 13.4% · cash 93.5%

Profitability 100=

return on assets 47.0%

Bankruptcy probability, 12 months

< 0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,155 companies, NACE 86, micro)

Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025highest value 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026lowest value

Credit of up to €23,000 on 30-day terms is acceptable

Liquidity ample (current ratio 7.38, compared with 6.47 in 2024, above the usual 1.5; short-term debt: 13.4% and cash: 93.5% of total assets), and 13.5% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 82% on solvency, 87% on liquidity, 80% on profitability and 92% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskneutral

Sector: Human health activities (NACE 86)

KBO

Liquidity: current ratio 7.38, cash €257,950

NBB · annual accounts

Equity €238,459 (86.5% of total assets)

NBB · annual accounts

Size: total assets €275,782

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-07-2026, 25 days ahead of the deadline.

NBB · 3 filings

Deviation from the deadline

2025

25 days early

2024

3 days early

2023

12 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 5 days before the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 July (3 of the last 3 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since incorporation in 2022.

KBO publications · our coverage

Key points

Positive: Equity rose in 2025from €108,939 to €238,459 ▲ 119% View

Documents

Annual accounts at the NBB

Annual accounts 2025filed on 06-07-2026
Annual accounts 2024filed on 28-07-2025
Annual accounts 2023filed on 12-08-2024

Acts in the Belgian Official Gazette

Incorporationact of 27-12-2022

All publications in the Belgian Official Gazette

Articles and registers

Coordinated articles of associationnotaries' database
Entry in the KBO registerKBO Public Search

Key facts about Dr. Jozefien Roose

What is the company number of Dr. Jozefien Roose?: 0795.265.881. In Belgium the VAT number is the company number with BE in front: BE 0795.265.881.
Where is Dr. Jozefien Roose based?: The registered office is at Splithage 24, 8340 Damme.Company details
What does Dr. Jozefien Roose do?: According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Dr. Jozefien Roose?: Private limited company (BV).
When was Dr. Jozefien Roose founded?: On 22-12-2022.
Is Dr. Jozefien Roose still active?: Yes, Dr. Jozefien Roose is an active enterprise in the KBO register.
What is the turnover of Dr. Jozefien Roose?: ≈ €310,000 in financial year 2025. Estimated from the gross margin of €168,446: probably between €270,000 and €420,000, based on 43 comparable companies, NACE 86220.Financials
Is Dr. Jozefien Roose profitable?: In financial year 2025, Dr. Jozefien Roose made a profit of €129,520.
Where can I find the annual accounts of Dr. Jozefien Roose?: Dr. Jozefien Roose filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of Dr. Jozefien Roose due?: By 31-07-2027, for financial year 2026.Timeline